Full FDA Approval of FILSPARI® (sparsentan): A Breakthrough for FSGS Patients
The FDA has granted full approval to FILSPARI® (sparsentan) as the first and only treatment for FSGS in adults and children aged 8+, expanding much-needed options in line with KDIGO guidelines and demonstrating significant reduction in proteinuria.